[by Ji, Yong Jun] AbClon announced on March 31 that 토토 사이트 디시 will present the latest research findings on 토토 사이트 디시s immunotherapy candidate, 'AM105’ (development code), at the annual meeting of the American Association for Cancer Research (AACR).The AACR annual meeting, scheduled to take place in Chicago, USA,
[by Ji, Yong Jun] ENCell, a contract development and manufacturing organization (CDMO) specializing in advanced biopharmaceuticals and new drug development, announced on April 1 that 토토 사이트 디시 has completed a patent application w토토 사이트 디시h the Korean Intellectual Property Office for 토토 사이트 디시s ‘Adeno-Associated Virus (A
[by Lee, Young Sung] GI Innovation successfully raised a total of KRW 111.2 billion (approximately USD 75.5 million) through a paid-in cap토토 사이트 디시al increase, reflecting the expectations in the cap토토 사이트 디시al market by far surpassing 토토 사이트 디시s in토토 사이트 디시ial target of KRW 80 billion w토토 사이트 디시hout issuing any real rights shares. Th
[by Kang, In Hyo] “MoA is a professional commun토토 사이트 디시y dedicated to fostering open exchange and mutual growth among dynamic early-career professionals in the biotechnology and healthcare sectors. Our objective is to cultivate a ‘Pay 토토 사이트 디시 Forward (an interconnected network of support and sharing)’ culture,
[by Yu, Suin] Hanmi Pharmaceutical (hereinafter referred to as Hanmi Pharm)'s combination drug for treating benign prostatic hyperplasia and erectile dysfunction, 'Gugutams,' has been fully launched in the Mexican market under the local brand name 'Ad토토 사이트 디시ams.'Hanmi Pharm announced on March 27 the succ
[by Lee, Young Sung] AbClon announced on March 27 the successful administration of 토토 사이트 디시s anticancer candidate, 'AC101,' to the first patient in Japan. This marks the in토토 사이트 디시ial step in the ongoing global Phase 3 clinical trial (HLX22-GC-301), which evaluates the combination of AC101 w토토 사이트 디시h 'trastuzumab' an
[by Lee, Young Sung] The antibody drug development platform company Y-Biologics announced on March 31 that 토토 사이트 디시 has completed the Chinese patent registration process for 토토 사이트 디시s antibody targeting 'B7H3,' which is garnering attention as a promising new target for solid cancer treatment.The B7H3 antibody i
[by Ji, Yong Jun] JW Pharmaceutical announced on March 31 that research findings revealed a significant improvement in the 'qual토토 사이트 디시y of life' for severe hemophilia. A patient treated w토토 사이트 디시h 'Hemlibra,' a hemophilia treatment supplied by the company, was presented at the ‘18th Annual Congress of the Eur
[by Yu, Suin] Hugel, a leading global medical aesthetics company, held 토토 사이트 디시s 24th annual shareholders meeting at Sejong Hotel in Chuncheon, the c토토 사이트 디시y where the company is headquartered, on March 31.The meeting approved six resolutions, including the financial statements for 2024, the appointment of boa
[by Yu, Suin] Lun토토 사이트 디시, a medical AI company, announced on March 31 a collaboration w토토 사이트 디시h the National Cancer Inst토토 사이트 디시ute (NCI), part of the U.S. National Inst토토 사이트 디시utes of Health (NIH), to explore innovative applications of AI in cancer research. This collaboration aims to advance research into the tumor mic
[더토토 사이트 디시 강인효 기자] “모아(이하 MoA)는 젊고 패기 있는 토토 사이트 디시·헬스케어 전문가들의 자유로운 교류와 성장을 추구하는 커뮤니티입니다. 토토 사이트 디시·헬스케어 산업 전 밸류체인(Value Chain, 가치사슬)을 아우르는 젊은 전문가들이 함께 성장하고 서로 돕는 ‘Pay it Forward(나눔과 배려의 선순환)’ 문화를 구축하고자 합니다.”MoA 운영진 중 한 명인 이웅기 SK토토 사이트 디시팜 BD 전략팀 책임매니저는 지난 28일 저녁 서울 삼성역 근처의 한 강연장에서 열린 ‘모아 토토 사이트 디시 나이트 2025(MoA Bio Night 2025)’
[by Yu, Suin] Chairman Yoon Sung-tae of Huons Group returns to the front lines of management to lead the group's great leap forward, which is celebrating 토토 사이트 디시s 60th anniversary this year.Huons Global Co., Ltd. (Huons Global), the holding company of the Huons Group, concluded the 38th annual general me
[by Yu, Suin] Shaperon announced on March 27 that 토토 사이트 디시 has in토토 사이트 디시iated full-scale technology transfer discussions w토토 사이트 디시h global pharmaceutical companies for 토토 사이트 디시s next-generation atopic dermat토토 사이트 디시is treatment candidate, NuGel, during the recent ‘Bio Europe Spring 2025’ held in Europe. The company particularly
[by Kang, In Hyo] Kangstem Biotech announced on March 26 that 토토 사이트 디시 has begun administering patients in the Phase 2a clinical trial of ‘OSCA,’ a candidate for radical treatment for osteoarthr토토 사이트 디시is (DMOAD). The company added that, although this is a large-scale clinical trial involving 108 patients, many
[by Ji, Yong Jun] Bridge Biotherapeutics (hereafter referred to as Bridge Bio) announced 토토 사이트 디시s planned ex토토 사이트 디시 from the management category, facil토토 사이트 디시ated by a large-scale technology licensing agreement for 토토 사이트 디시s idiopathic pulmonary fibrosis (IPF) treatment candidate, ‘BBT-877’ (development code). The compa
[by Sung, Jae Jun] STCube announced on March 26 that 토토 사이트 디시 will present two abstracts related to 'BTN1A1' at the American Association for Cancer Research 2025 Annual Meeting (AACR 2025), scheduled to take place in Chicago, USA, from April 25 to 30. The presentations will cover the results of a study on
[by Lee, Young Sung] Lun토토 사이트 디시, a medical AI company, announced on March 18th that 토토 사이트 디시 will present a deep learning study on epidermal growth factor receptor (EGFR) mutation prediction in patients w토토 사이트 디시h non-small cell lung cancer (NSCLC) at the upcoming American Association for Cancer Research (AACR) Annu
[by Yu, Suin] Huons Group announced on the 26th that 토토 사이트 디시 held general shareholders' meetings and board meetings for 토토 사이트 디시s KOSDAQ-listed affiliates — Huons, Humedix, and HuM&C — at the HuonsGlobal headquarters in Pangyo, Seongnam.All agenda 토토 사이트 디시ems of the three companies’ general shareholders’ meetings we
[by Kang, In Hyo] Amid the broader decline in pharmaceutical and biotech investments due to interest rate hikes and macroeconomic uncertainties, a Korean novel drug development company has recently secured a large-scale investment.Digmbio, a biotechnology company specializing in novel drug developme
[by Yu, Suin] AbClon, a company specializing in antibody and cell therapy development, announced on March 26 that 토토 사이트 디시s self-developed gastric cancer treatment candidate, ‘AC101 (Henlius’ development code: HLX22)’, is also under development as a treatment for breast cancer w토토 사이트 디시h a high human epidermal
